Alkem Laboratories Ltd - Company Profile
Powered by 
All the sales intelligence you need on Alkem Laboratories Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Alkem Laboratories Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Alkem Laboratories Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Alkem Laboratories Ltd (Alkem) manufactures, develops, and markets generic and specialty pharmaceutical products. The company's major activities include the manufacturing and marketing of pharmaceutical products across multiple therapeutic areas such as anti-infective, pain relief/analgesic, gastroenterology, dermatology, anti-diabetic, cardiology, and neurology/central nervous system (CNS). The company’s product portfolio includes active pharmaceutical ingredients, generic products, branded products, and nutraceuticals. It also offers vitamins, minerals, and nutritional products. The company exports products to Germany, Australia, Southeast Asia, the US, the UK, Russia-CIS, and Africa. Alkem is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
Devashish Building, Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai, Maharashtra, 400013
Website
www.alkemlabs.com
Telephone
91 22 39829999
No of Employees
18,642
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALKEM (NSE)
Revenue (2025)
$1.7B
13.5%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
6.3%
(2025 vs 2024)
Market Cap*
$7.0B
Net Profit Margin (2025)
XYZ
-6.3%
(2025 vs 2024)
* As of and is in US$
Alkem Laboratories Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Therapeutic Areas: | Clavam |
| Vitamin and Nutrition | Pan |
| Cancer | Pan-D |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In March, the company launched semaglutide injection in India. |
| 2026 | New Products/Services | In January, the company introduced the Renocia cyclical therapy kit, a scientifically-designed weekly nutritional supplementation regimen. |
| 2025 | New Products/Services | In September, the company launched Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India. |
Competitor Comparison
| Key Parameters | Alkem Laboratories Ltd | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Aurobindo Pharma Ltd | Cipla Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Mumbai | Mumbai | Hyderabad | Hyderabad | Mumbai |
| State/Province | Maharashtra | Maharashtra | Telangana | Telangana | Maharashtra |
| No. of Employees | 18,642 | 47,000 | 27,527 | 9,107 | 31,369 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Basudeo N. Singh | Chairman | Executive Board | - | - |
| Dr. Vikas Gupta | Chief Executive Officer | Senior Management | - | - |
| Nitin Agarwal | President; Chief Financial Officer | Senior Management | 2024 | - |
| Ramanarayana Parhi | Vice President; Chief Information Officer | Senior Management | 2023 | - |
| Sandeep K. Singh | Managing Director; Director | Executive Board | 2013 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer